05/14/2019
IsoPlexis completes $25 Million Series C financing
04/11/2019
Spring Mountain Capital participates in Artivest Alternative Investment Summit
04/09/2019
Keen Decision Systems announces Series A investment from Spring Mountain Capital
02/21/2019
Paul Gilbert joins the SMC Growth Capital Partners II Strategic Advisory Board
02/15/2019
Oncoceutics licenses rights to ONC201 for Japan to Ohara Pharmaceutical
02/01/2019
Oncoceutics featured in People Magazine for its promise in treating brain tumors
01/22/2019
Spring Mountain Capital completes successful exit of Activate Healthcare
11/26/2018
Spring Mountain Capital’s Launny Steffens speaks at the Stanford Graduate School of Business
11/12/2018
FDA grants fast track designation to ONC201 for the treatment of Adult Recurrent H3 K27M-mutant High-Grade Glioma
10/18/2018
Spring Mountain Capital hosts presentation on artificial intelligence & robotics by Dr. Henrik Christensen
9/26/2018
Maven raises $27 million in Series B funding led by Sequoia Capital and Oak HC/FT
8/07/2018
RiskSense raises $12MM in Series B funding round co-led by Spring Mountain Capital and NightDragon Security
6/22/2018
Utz Quality Foods treats employees with Activate Healthcare onsite healthcare clinic
6/13/2018
Doctor.com recognized by Google as the only Google My Business (GMB) partner focused on healthcare
6/12/2018
IsoPlexis collaborates with Kite Pharma to publish clinical data in Blood highlighting the potential to predict which cancer patients will respond to CAR-T cell therapy
Vergent Bioscience raises $8.7 million in Series A financing led by Spring Mountain Capital
5/14/2018
IsoPlexis named as a top 10 analytics solution provider by Pharma Tech Outlook
5/07/2018
ReNetX Bio closes financing with Spring Mountain Capital
5/04/2018
OpenSlate’s Mike Henry discusses importance of brand safety with Bloomberg
4/09/2018
State of Arizona selects the RiskSense platform to monitor and manage cyber security risk
3/31/2018
Maven named as a top female-founded startup that is expected to take off in 2018
3/20/2018
Home Captain closes Series A financing with Spring Mountain Capital
3/15/2018
Spring Mountain Capital leads $8 million Series B financing in 180 Health Partners
3/14/2018
Maven Clinic announces new partnership with Castlight Health to offer comprehensive parental support platform to customers
1/31/2018
ONC201 trial begins at NYU for children with H3 K27M mutant glioma
1/05/2018
Maven’s Kate Ryder forecasts what will happen in women’s health in 2018 in Forbes
1/03/2018
Doctor.com’s David Murray shares his secrets to building great company culture in Forbes
12/13/2017
Doctor.com and Connect Healthcare announce merger to deliver the only complete solution to power the digital patient journey
12/11/2017
IsoPlexis wins 2017 Fierce Technology Innovation Award
12/01/2017
The Scientist names IsoPlexis technology the top innovation of 2017
11/15/2017
IsoPlexis receives $5.6 million in NIH funding to develop next-generation single-cell assay products, technologies and applications
10/24/2017
Maven’s Katherine Ryder shares her venture capital insights
10/23/2017
IsoPlexis receives $1.8M National Cancer Institute grant
10/13/2017
New Maven report: Why Investing in Return-to-Work Benefits is a Billion Dollar Opportunity for Companies
9/7/2017
Ad firms enlist OpenSlate to make sure ads run with “safe” YouTube videos
8/15/2017
Doctor.com launches the first universal “Web-Wide” online scheduling solution for healthcare providers
7/25/2017
Spring Mountain Capital leads $10.8 million Series A in digital health company Maven
Maven lands $11 million Series A to disrupt women’s health care
5/25/2017
Doctor.com and Healthgrades partner to help healthcare providers manage their online presence
5/8/2017
SimpleReach announces $13 million in funding, names MarTech veteran Hal Muchnick CEO
4/3/2017
IsoPlexis collaboration offers breakthrough insights into detecting and predicting patient response to T-cell therapy
2/23/2017
Doctor.com closes $5 million Series A financing led by Spring Mountain Capital
11/28/2016
Spring Mountain Capital completes successful exit of Prevalent to Insight Venture Partners
8/9/2016
ONC201 leads Oncoceutics to new imipridone class of cancer drugs
6/27/2016
Spring Mountain Capital’s Launny Steffens delivers the keynote speech to investors at the Amsterdam Private Equity Club (APEC) in the Netherlands
3/14/2016
Hurel providing cell-based models to EPA’s TOXCAST program
2/24/2016
U.S. patent issued for ONC201 composition of matter
2/16/2016
Science Signaling companion articles describe ONC201 mechanism of action
1/19/2016
Prevalent launches Legal Vendor Network
1/11/2016
Spring Mountain Capital leads $8 million Series B financing in Prevalent
11/6/2015
IsoPlexis appoints academic and industry experts to inaugural scientific advisory board
10/22/2015
Outrigger’s OpenSlate data shows a surge in ad-supported YouTube channels
10/6/2015
Spring Mountain Capital leads Series A financing for Oncoceutics
7/21/2015
Ziften announces general availability of Ziften v4.5
7/15/2015
Spring Mountain Capital leads $24 million investment in Ziften
7/9/2015
Oncoceutics announces completion of ONC201 first-in-man study
6/29/2015
Spring Mountain Capital leads new round of financing in Activate Healthcare
5/18/2015
Giga-tronics finalizes $10.0 Million order for high-performance YIG tuned filter products
5/13/2015
Giga-tronics receives $3.0 Million order for high-performance YIG tuned filter products
5/5/2015
Oncoceutics announces publication of a research article in the journal Molecular Cancer that describes the discovery of ONC201 as a selective anti-cancer agent
4/29/2015
Disney’s Maker Studios partners with Outrigger Media to sell ads across all of YouTube
4/28/2015
Maker Studios partners with Outrigger’s OpenSlate to enable advertisers to purchase ad space on all YouTube channels
4/20/2015
Optivia Biotechnology forms technology & marketing alliance with Hurel Corporation
3/31/2015
Oncoceutics selected to present at the 106th Annual Meeting of the American Association for Cancer Research
Oncoceutics awarded NCI grant for clinical trial of ONC201 in glioblastoma multiforme
3/5/2015
Experimental cancer drug from Oncoceutics could be fast-tracked, says exec
3/3/2015
Phase I trials begin on Oncoceutics’ ONC201 at Rutgers Cancer Institute of New Jersey
3/2/2015
Giga-tronics announces a $1.6M strategic investment by AVI Partners, LLC and regains compliance with Nasdaq listing requirements
2/25/2015
An article in the journal Cancer Research indicates that Oncoceutics’ ONC201 eradicates cancer stem cells in colorectal cancer
1/13/2015
Outrigger Media raises $5.2 Million, adds YouTube demographics to OpenSlate
12/23/2014
Trimble acquires IRON Solutions to broaden its connected farm solution for growers, Ag dealers and agronomists
10/1/2014
ACEA Biosciences and Hurel Corporation announce joint marketing of integrated product kits
9/29/2014
Spring Mountain Capital leads investment in Oncoceutics
9/24/2014
Hurel Corporation completes investment from Johnston Associates, Inc.
9/3/2014
Spring Mountain Capital leads investment in Activate Healthcare
8/5/2014
Spring Mountain Capital leads investment in IsoPlexis Corporation
4/7/2014
Spring Mountain Capital’s Jamie Weston discusses Giga-tronics and American Power Group in an interview about private equity investing with thestreet.com
2/6/2014
The December/January issue of Buyout Magazine, in a cover story titled, “Deal-making sluggish as giants move down-market,” quotes Spring Mountain Capital’s Jamie Weston regarding growth-related opportunities in private equity (subscription required)
The HFMWeek article, “Exclusive: Spring Mountain to launch long/short equity FoHF,” breaks the news that Spring Mountain Capital is launching a dedicated long/short equity fund of hedge funds (subscription required)
10/29/2013
Cisco completes acquisition of WhipTail
10/1/2013
Hurel enters into cell-based R&D collaboration with Sanofi US to validate HurelHuman in vitro liver tissue co-culture for use in pre-clinical drug development
9/10/2013
Cisco announces intent to acquire WhipTail for $415 million
7/16/2013
Hurel Corporation launches cell-based in vitro testing product suite, milestone in movement away from use of live animals in drug and toxicity testing
4/3/2013
Hurel receives $9.2 Million Series A funding from Spring Mountain Capital
